FindTrial
Sign In

Corneal Toxicity of Belantamab Mafodotin in Relapsed Myeloma: A Longitudinal Clinical Analysis

Corneal Toxicity of Belantamab Mafodotin in Relapsed Myeloma: A Longitudinal Clinical Analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500106444
Enrollment
Unknown
Registered
2025-07-23
Start date
2025-07-23
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed/refractory multiple myeloma,Keratopathy

Interventions

Observation group:None

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Patients with frontal RRMM who received BM monoclonal antibody treatment at West China Hospital, Sichuan University

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
Corneal lesion condition;—

Countries

China

Contacts

Public ContactTang jing

West China Hospital of Sichuan University

tangjing0802@163.com+86 189 8060 3835

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026